Cyclopharm Limited · ASX:CYC
Cyclopharm — 8th Annual Australian Microcap Investment Conference 2017
25 slides from Cyclopharm's conference presentation, Oct 18, 2017
Slide 1: Cyclopharm Limited
Cyclopharm Limited A profitable and growing market leader in nuclear lung imaging 8th Annual Australian Microcap Investment Conference 18 October 2017 1
Slide 2: Company Overview
Company Overview Cyclopharm Limited (CYC) is a leading diagnostic lung imaging company • A world leader in functional lung ventilation imaging technology • Recurring consumables and capital equipment revenue streams • A profitable and growing company with a history of dividend payments • Lead nuclea
Slide 3: Our Strategy
Our Strategy CYC has clear strategy to leverage our position as a leading player in the global nuclear medicine imaging market and lung health space to expand the use of our proprietary products and introduce new innovative technology. We will do this by: 1. Attaining approval to distribute Technega
Slide 4: 1H2017 Results Highlights
1H2017 Results Highlights • Group Sales Revenue $6.06 million • Gross Margin $5.00 million • Net Loss After Tax ($1.43) million • Interim Dividend 0.5 cents per share • Underlying Technegas EBITDA1 $861,000 • FDA Trial expenses ($1.58) million • Strong balance sheet $10.62 million of cash reserves •
Slide 5: Company Overview
Company Overview Cyclopharm’s leading product is the Technegas technology system The Technegas proprietary technology provides high quality diagnostic functional lung imaging. Predominantly used to diagnose the presence of blood clots in the lung otherwise known as Pulmonary Embolisms (PE), with
Slide 6: Proven Market Adoption
Proven Market Adoption Technegas is a substantially de-risked commercial proposition with significant upside in the US market Total global sales of $83m since 2010 Technegas currently available in 56 countries Over 210,000 patient procedures in 2016 Over 3,800,000 patient procedures since 19
Slide 7: FDA Trial and USA Commercialisation
FDA Trial and USA Commercialisation 7
Slide 8: USA Market Opportunity
USA Market Opportunity 600K Nuclear Medicine Ventilation Target market for Technegas in the USA equates to ~480,000 patient procedures of the total 600,000 Procedures p.a. = $90m USD procedures conducted p.a.in that market (Current 15% Rest of the World volumes for Technegas = 600K ~200,000 patien
Slide 9: Advantages of Technegas
Advantages of Technegas Technegas provides clinically superior outcomes to its Competitive Nuclear Medicine Products competitors Better clinical results at a fraction of the high radiation doses Product Comparison to Technegas used in CTPA (angiograms) No contraindications Patient has to conti
Slide 10: Technegas FDA Clinical Trial Process and Design
Technegas FDA Clinical Trial Process and Design Study Specifics: • Non-inferiority structural ventilation study comparing Xe133 vs. Technegas • Pathway to approval requires a two part study CYC 010 – Establishes the Inter & Intra reader variability for Xe133 – Completed CYC 009 - Compares Xe133
Slide 11: Technegas – The Canadian Case Study
Technegas – The Canadian Case Study Canada is Cyclopharm’s largest single country market The Generator and Consumable Relationship 50,000 140 • Market leader for diagnosing PE Technegas Growth - Canada 45,000 • 13 consecutive years of PAS growth Active Generators 120 40,000 Patients per • Represents
Slide 12: Pathway to US commercialisation
Pathway to US commercialisation New Manufacturing Facility Q4 2016 – Increased capacity to meet future demand & regulatory requirements Target preliminary study completion Q1 2018 – Conclude a preliminary study of 40 patients and receive feedback from the FDA. Target FDA Trial completion Q3 20
Slide 13: Technegas Indication expansion – Australian Initiative
Technegas Indication expansion – Australian Initiative • Partnership with the University of Newcastle, John Hunter Hospital and Hunter Medical Research Institute • Targeting Clinical Applications in COPD Patients • Clinical Hypothesis: Small airway dysfunction assessed using Technegas functional lun
Slide 14: 2017 Strategic Priorities and Outlook
2017 Strategic Priorities and Outlook Strategic Goals & Activity Timeframe Guidance United States • $7m raised to fund USFDA clinical trial with >90% shareholder participation Q2 2017 FDA Approval • Patient recruitment initiated Q3 2017 • Complete clinical site recruitment Q4 2017 • Complete Techneg
Slide 15: Thank you & Questions
cyclopharm #@ L . as d Nuclear Medicine = Thank you & Questions
Slide 16: Appendix
Appendix 1H FY17 Results Technegas UltraluteTM MMI Disclaimer 16
Slide 17: 1H2017 Operating Highlights
1H2017 Operating Highlights Technegas continuing to perform well – Volume of Technegas generators sold increased 7% vs pcp. Unit sales of PAS, excluding the French and Chinese markets, increased 6% vs pcp. Ultralute on track for 2H sales – First commercial batch of Cyclopharm’s new patented Ultr
Slide 18: Group 1H2017 Underlying Performance
Group 1H2017 Underlying Performance During the half year, CYC continued to implement Solid Underlying Financial Results its strategic priorities, which are to: 1. Grow the core business, based on expanding Half Year ended 30 June 2017 2016 Technegas sales in existing markets; ($000’s) Consolidated s
Slide 19: Group 1H2017 Balance Sheet
Group 1H2017 Balance Sheet Financial Foundation to Leverage Growth Strategy Debt free & $10.6m cash on hand – provides balance sheet and funding 30 June 31 Dec flexibility ($000’s) 2017 2016 Funding used toward USFDA clinical trial Cash 10,620 4,591 Other current assets 5,710 6,470 enrolment and
Slide 20: Cash Position
Cash Position Solid Cash Generation & Funded for Growth Successful Capital Raising ($000’s) HY 2017 FY 2016 Operating Activities (189) 655 Completed a fully-underwritten Investing Activities (546) (2,221) Entitlement Offer that raised Financing Activities 6,311 (754) $6.59 million after costs. Net
Slide 21: What is Technegas?
What is Technegas? Technegas is a System Technegas is the world leader in functional lung ventilation imaging. In order to deliver the best clinical outcomes, Technegas requires the combination of authorised: • Technegas is a structured ultra-fine dispersion of radioactive gas like substance which i
Slide 22: FDA Approved Trial Design
FDA Approved Trial Design De-risked clinical trial strategy - In order to mitigate regulatory risk the Company adopted the FDA Special Protocol Assessment (SPA) pathway for its US clinical trial FDA approved trial design - The SPA pathway provided the Company with the opportunity to reach agreem
Slide 23: Ultralute
UltraluteTM Innovative, first-in-class, disruptive, proprietary technology used to improve radiopharmaceutical manufacturing efficiency and deliver health care cost effectiveness Technical Features • Extension of Generator life – the Ultralute will extend the effective use of an Mo99 generator by up
Slide 24: Macquarie Medical Imaging
Macquarie Medical Imaging • Joint venture with: • 50% Alfred Health Solutions CT MRI PET • 30% Macquarie University • 20% Cyclopharm • Comprehensive suite of imaging modalities • State of the art research platform • Growth and profitability linked to ramp-up Cardiac CT Ultra-sound SPECT of Macquarie
Slide 25: Disclaimer
Disclaimer Corporate Head Office Certain views expressed here contain information derived from publicly available sources that have not Cyclopharm Limited been independently verified. Unit 4, 1 The Crescent Kingsgrove NSW 2208 Australia The presentation include certain statements, estimates and proj
Cyclopharm — 8th Annual Australian Microcap Investment Conference 2017 on 6ix